Beijing Minhai Biological

Beijing Minhai Biological Technology Co., Ltd. is a leading Chinese biopharmaceutical company specializing in the research, development, and manufacturing of human vaccines. Founded in 2004 and operating as a subsidiary of Shenzhen Kangtai Biological Products (Bio-Kangtai), the company maintains a large-scale, GMP-certified manufacturing base in Beijing's Daxing District. Minhai is recognized for its innovation in combination and multivalent vaccines, notably producing the world's first dual-carrier 13-valent pneumococcal conjugate vaccine and China's first domestic tetravalent DTaP-Hib vaccine. The company manages a robust pipeline of over 25 vaccine candidates targeting various infectious diseases, including rabies, polio, and HPV. Minhai is actively expanding its global footprint through international registrations and WHO prequalification efforts across Asia, Africa, and South America.